Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (603392) responded to investor inquiries on November 5, stating that the company maintains regular communication with the capital market through various channels, including investor hotlines, strategy meetings, E-interaction, and earnings briefings.